InnoCare Pharma (HKG: 9969; SHA: 688428) announced its third-quarter 2026 financial results, reporting Q3 total revenue of RMB 962 million, up 150.6% year on year, and first-nine-month (9M) revenue of RMB 2.099 billion, up 88.21% YoY. The company sustained profitability in the third quarter, with 9M net profit of RMB 648 million — a turnaround to profitability versus a loss in the same period last year.
Q3 & 9M 2026 Financial Highlights
| Item | Detail |
|---|---|
| Q3 Total Revenue | RMB 962 million, +150.6% YoY |
| Q3 Drug Sales Revenue | RMB 530 million, +38.59% YoY |
| 9M Total Revenue (Jan–Sep) | RMB 2.099 billion, +88.21% YoY |
| 9M Drug Sales Revenue | RMB 1.449 billion, +41.47% YoY |
| 9M Net Profit | RMB 648 million — turnaround to profitability vs. 9M 2025 |
| Q3 Profitability | Sustained (profitable for the quarter) |
Growth Drivers
- Core Product Momentum: Continued sales expansion of orelabrutinib, InnoCare’s flagship BTK inhibitor, remained the primary revenue engine.
- New Product Contributions: Additional sales from tafasitamab (anti‑CD19 monoclonal antibody) and zurletrectinib (next‑generation TRK inhibitor) broadened the commercial portfolio.
- Licensing Milestones: Delivery of subsequent milestones under the licensing agreement with Zenas BioPharma accounted for a significant share of the outsized total-revenue growth beyond drug sales.
Market Impact & Outlook
- Inflection to Profit: The RMB 648 million 9M net profit marks InnoCare’s transition from R&D‑stage cash burn to self‑sustaining operations — a milestone closely watched for China’s biotech sector.
- Revenue Mix: With Q3 drug sales (+38.59%) growing more slowly than total revenue (+150.6%), licensing milestone income amplified headline growth; the durability of product‑level momentum rests on orelabrutinib’s continued uptake.
- Portfolio Depth: Commercial contributions from three distinct assets — orelabrutinib, tafasitamab, and zurletrectinib — reduce single‑product concentration risk as the company scales.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding InnoCare Pharma’s revenue trajectory, product commercialization, licensing milestone deliveries, and profitability sustainability. Actual results may differ due to risks including market competition, reimbursement dynamics, regulatory outcomes, and timing of future milestone payments.-Fineline Info & Tech
